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SIRT1The aspartyl proteaseβ-site AβPP-cleaving enzyme1 (BACE1) catalyzes the rate-limiting step inAβ production, a
peptide at the nexus of neurodegenerative cascades in Alzheimer Disease (AD). The adipocytokine leptin has
been demonstrated to reduce Aβ production and decrease BACE1 activity and expression levels. However, the
signaling cascades involved in the leptin-induced mitigation in Aβ levels and BACE1 expression levels have not
been elucidated. We have demonstrated that the transcription factor nuclear factor – kappa B (NF-κB) positively
regulates BACE1 transcription. NF-κB activity is tightly regulated by the mammalian sirtuin SIRT1. Multiple
studies have cogently evinced that leptin activates the metabolic master regulator SIRT1. In this study, we
determined the extent to which SIRT1 expression and activity regulate the leptin-induced attenuation in
BACE1 expression and Aβ levels in cultured human neuroblastoma SH-SY5Y cells. This study also elucidated
and delineated the signal transduction pathways involved in the leptin induced mitigation in BACE1 expression.
Our results demonstrate for the ﬁrst time that leptin attenuates the activation and transcriptional activity of
NF-κB by reducing the acetylation of the p65 subunit in a SIRT1-dependent manner. Furthermore, our data
shows that leptin reduces the NF-κB-mediated transcription of BACE1 and consequently reduces Amyloid-β
genesis. Our study provides a valuable insight and a novelmechanism bywhich leptin reduces BACE1 expression
and Amyloid-β production and may help design potential therapeutic interventions.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer Disease (AD) is the most prevalent neurodegenerative
disorder debilitating almost one-fourth of the geriatric population
over the age of 80 [1]. AD is neuropathologically characterized by
deposition of Amyloid-β (Aβ) as extracellular plaques, accumulation
of phosphorylated neuroﬁbrillary protein tau (τ) as intracellular tan-
gles, and progressive neuronal loss. Familial AD comprising about 5%
of AD cases is attributable to geneticmutations in the amyloid precursor
protein (APP) and presenilin 1 and2 (PSEN1 and2) genes. However, the
majority of AD cases are sporadic in nature with no known etiology.
Contemporary evidence implicates aging as the single most important
risk factor in the susceptibility to sporadic AD. Furthermore, other un-
derlying pathological processes implicated in the etiology of AD such
as oxidative stress, protein misfolding, inﬂammation and disruption of
calcium homeostasis, all increase with aging [2,3]. A preponderance of
studies have implicated SIRT1, a NAD+-dependent class III histone
deacetylase (class III HDAC, Sirtuin), in combating aging and extending
lifespan [3–8], inhibiting apoptosis [9], and regulating metabolism [10,y, Physiology and Therapeutics,
Sciences, 501 North Columbia
2; fax: +1 701 777 4490.
bi).11]. SIRT1 attenuates Aβ-induced toxicity in rat primary neuronal cul-
tures by the inhibition of NF-κB signaling [12]. A plethora of studies
have demonstrated the activation role of NF-κB in BACE1 transcription
[13–20], thereby suggesting that SIRT1 may regulate Aβ production by
modulating BACE1 expression via NF-κB signaling. Furthermore,
Donmez et al. have recently demonstrated that SIRT1 suppresses Aβ
production by inducing the transcription of the α-secretase, ADAM10
[21] and swaying APP processing toward the non-amyloidogenic path-
way. SIRT1 overexpression renders a neuroprotective effect in models
of AD [22] and neuronal SIRT1 activation underlies the mechanism of
preclusion of AD neuropathology by caloric restriction [23].
A multitude of studies have implicated leptin, an adipocytokine, in
the attenuation of Aβ production [24–30]. Epidemiological studies
have suggested an inverse relationship between leptin levels and
development of AD [31] and lower circulating leptin levels have been
reported in AD patients [32]. Recent evidence suggests that SIRT1 acti-
vation and expression is essential for leptin-induced anorexic effects
via the expression of POMC in the POMC neurons in the hypothalamus
[33]. Moreover, leptin deﬁcient ob/obmice do not exhibit SIRT1 activa-
tion in the hypothalamus in response to caloric restriction compared to
age-matched controls [34]. Leptin receptor mutant db/dbmice exhibit
analogous lack of SIRT1 activation in the hypothalamus [35]. This sug-
gests that leptin signaling in the hypothalamus results in the activation
of SIRT1 and activated SIRT1 is necessary for leptin-induced effects on
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the hippocampus and other areas of the brain affected by AD. It is
therefore conceivable and tempting to assume an analogous effect of
leptin on SIRT1 activation in other areas of the brain. As SIRT1negatively
regulates NF-κB mediated transcription of target genes, and given the
positive role of NF-κB in BACE1 transcription, we hypothesized that
leptin-induced attenuation in BACE1 expression levels and subsequent
reduction in Aβ levels involves SIRT1 activation. This study determined
the extent to which leptin regulates Aβ levels via the modulation of
SIRT1 expression levels. We tested the hypothesis that leptin reduces
Aβ levels by attenuating BACE1 expression levels via the increase in
SIRT1 expression levels and concomitant activation of SIRT1 signaling.2. Material and methods
2.1. Reagents
Leptin and Sirtinol were purchased from Sigma Aldrich (Saint Louis,
MO). All cell culture reagents, with the exception of fetal bovine serum
(Atlanta Biologicals, Lawrenceville, GA) and antibiotic/antimycotic mix
(Sigma Aldrich, Saint Louis, MO) were purchased from Invitrogen
(Carlsbad, CA). Human SH-SY5Y neuroblastoma cells were purchased
from ATCC (Manassas, VA).2.2. Cell culture and treatments
Human neuroblastoma SH-SY5Y cells were grown in Dulbecco's
modiﬁed Eagle's medium: Ham's F12 with Glutamax (1:1; v/v), 10%
fetal bovine serum, and 1% antibiotic/antimycotic mix. Cells weremain-
tained at 37 °C in a saturated humidity atmosphere containing 95% air
and 5% CO2. After having reached 80% conﬂuence, cells were incubated
with vehicle (control), 10nM leptin, 400 μM Sirtinol, and 10nM
leptin + 400 μM Sirtinol, for 24 h at 37 °C in cell medium.2.3. Western blot analysis
Treated SH-SY5Y cells were washedwith PBS and trypsinized to col-
lect the cells and centrifuged at 5000 g. The pellet was washed again
with PBS and homogenized in NE-PER tissue protein extraction reagent
(ThermoScientiﬁc, Rockford, IL) supplementedwith protease andphos-
phatase inhibitors. Protein concentrations from the cytosolic and
nuclear homogenates were determined with BCA protein assay.
Proteins (10 μg) were separated in SDS-PAGE gels followed by transfer
to a polyvinylidene diﬂuoridemembrane (BioRad, Hercules, CA) and in-
cubation with the following monoclonal antibodies: anti-SIRT1 mouse
antibody (1:1000; Cell Signaling, Boston, MA), anti NF-κB p65 mouse
antibody (1:1000; Cell Signaling, Boston, MA), anti NF-κB p50 mouse
antibody (1:1000; Cell Signaling, Boston, MA), anti-Acetyl Lys310
NF-κB p65 rabbit antibody (1:100; Cell Signaling, Boston, MA), and
anti-BACE1 mouse antibody (1:500; Millipore, Bedford, MA). β-actin
and Lamin A/C were used as a gel loading control for cytosolic homoge-
nates and nuclear homogenates respectively. All the PVDF membranes
used for immunoblotting and probing of primary targets were stripped
using the commercially available “Restore Western Blot Stripping
Buffer” from Pierce Thermo Scientiﬁc. The PVDF membranes were sub-
sequently reprobed with antibodies against β-actin or Lamin as loading
controls for normalization. The blots were developed with enhanced
chemiluminescence (Immmun-star HRP chemiluminescent kit,
Bio-Rad, Hercules, CA). Bands were visualized on a polyvinylidene
diﬂuoride membrane and analyzed by LabWorks 4.5 software on a
UVP Bioimaging System (Upland, CA). Quantiﬁcation of results was per-
formed by densitometry and the results analyzed as total integrated
densitometric values (arbitrary units).2.4. Enzyme-linked immunosorbent assay (ELISA)
Aβ40 and Aβ42 levels were quantiﬁed in the media (secreted) and
cellular homogenates (intracellular) using an ELISA immunoassay kit
(Invitrogen, Carlsbad, CA) as per themanufacturer's protocol. Following
treatments, the culture medium was collected, supplemented with
protease and phosphatase inhibitors cocktail, and centrifuged at
16,000 g for 5 min at 4 °C. 100 μL of supernatant was used for the quan-
tiﬁcation of secreted Aβ40 and Aβ42 levels by colorimetric sandwich
ELISA according to the manufacturer's protocol. To measure the levels
of intracellular Aβ40 and Aβ42 in the cellular homogenates, cells were
trypsinized and collected by centrifugation at 5000 g and the cell pellet
(~100 mg) was homogenized thoroughly with 8× mass of cold 5 M
guanidine HCl/50 mM Tris–HCl. The homogenates were mixed for 3–4
h at room temperature. The samples were diluted with cold reaction
buffer (Dulbecco's phosphate-buffered saline with 5% BSA and 0.03%
Tween-20 supplemented with 1× protease inhibitor cocktail) and cen-
trifuged at 16,000 g for 20 min at 4 °C. The supernatant was decanted,
diluted at 1:1with standard diluent buffer, and quantiﬁed by colorimet-
ric sandwich ELISA kits. Intracellular Aβ levels in the cellular homoge-
nates were normalized to total protein content in the samples.
Treatments were performed in quadruplet, and the quantity of Aβ in
each sample was measured in duplicate. The secreted Aβ40 and Aβ42
levels measured in the culture medium are expressed in pg/mL of
media.
2.5. Quantitative real time RT-PCR analysis
Total RNA was isolated and extracted from treated cells using the 5
prime “PerfectPure RNA tissue kit” (5 Prime, Inc., Gaithersburg, MD).
RNA estimation was performed using “Quant-iT RNA Assay Kit” using
a Qubit ﬂuorometer according to the manufacturer's protocol
(Invitrogen, Carlsbad, CA). cDNA was obtained by reverse transcribing
1 μg of extracted RNA using an “iScript cDNA synthesis kit” (BioRad,
Hercules, CA). The oligomeric primers (Sigma, St Louis, MO) used to
amplify the SIRT1 mRNA and BACE1 mRNA are enumerated in Table 1.
The cDNA ampliﬁcation was performed using an iQ SYBR Green
Supermix kit following the manufacturer's instructions (BioRad,
Hercules, CA). The ampliﬁcation was performed using an iCycler iQ
Multicolor Real Time PCR Detection System (BioRad, Hercules, CA).
The expression of speciﬁc SIRT1 and BACE1 transcripts ampliﬁed was
normalized to the expression of glyceraldehyde-3-phosphate dehydro-
genase (GAPDH).
2.6. Chromatin immunoprecipitation (ChIP) analysis
ChIP analysis was performed to evaluate the extent of NF-κB binding
to theDNA elements in the BACE1 promoter region using “SimpleChIP™
Enzymatic Chromatic IP kit” from Cell Signaling (Boston, MA) using a
protocol as previously described [37–39]. Brieﬂy, cells from each treat-
ment group (3 × 106 cells) were washed with PBS, trypsinized,
centrifuged at 5000 g. The pellet was further washed with PBS and
cross-linked using 37% formaldehyde for 15 min followed by the
addition of glycine solution to cease the cross-linking reaction. Cells
were washed with 4× volumes of 1× PBS and centrifuged at ~220 g
for 5 min. The pellet was resuspended and incubated for 10 min in
5 mL of cell lysis buffer containing DTT and protease inhibitor provided
with the kit and phosphatase inhibitorswere added separately. The cells
were Dounce homogenized and sonicated to shear the DNA. The ho-
mogenates were centrifuged at 1000 g and the pellet was resuspended
in a buffer containingDTT (providedwith the kit). 5% ofmicrococcal nu-
clease (providedwith the kit)was added to each tube to digest DNA to a
length ranging approximately from 150 to 900 bp for 20 min at room
temperature followed by stopping the digest by the addition of 100 μL
of 0.5 M EDTA. The homogenates were now centrifuged at 15,000 g
for 2 min and the pellet was resuspended and incubated for 10 min in
Table 1
List of primers designed and used for PCR and ChIP analyses.
Gene Primer GenBank accession number Sequence Species Application
SIRT1 Forward1 NM012238 5′-cagtggctggaacagtgaga-3′ Human RT-PCR
SIRT1 Reverse1 NM012238 5′-tctggcatgtcccactatca-3′ Human RT-PCR
SIRT1 Forward2 NM012238 5′-tcagtggctggaacagtgag-3′ Human RT-PCR
SIRT1 Reverse2 NM012238 5′-tctggcatgtcccactatca-3′ Human RT-PCR
SIRT1 Forward3 NM012238 5′-ttcagtggctggaacagtga-3′ Human RT-PCR
SIRT1 Reverse3 NM012238 5′-tctggcatgtcccactatca-3′ Human RT-PCR
BACE1 Forward NT033899 5′-tgaggcaggcagataacttg-3′ Human ChIP
BACE1 Reverse NT033899 5′-gcctcctcaagcgattctc-3′ Human ChIP
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lysates were sonicated to disrupt the nuclear membrane and centri-
fuged at 15,000 g for 15 min. The cross-linked chromatin from each
sample was apportioned into three equal parts. One third of the cross-
linked chromatin was set aside as “input”. One third of the cross-
linked chromatin from each sample was incubated with 5 μg of anti
NF-κB p65 mouse antibody (1:1000; Cell Signaling, Boston, MA),
while the remaining one third of the cross-linked chromatin from
each sample was incubated with 5 μg of normal Rabbit IgG to serve as
negative control. The cross-linked chromatin samples were incubated
overnight at 4 °C with their respective antibodies. The DNA–protein
complexes were collected with Protein G agarose beads and washed
to remove non-speciﬁc antibody binding. The DNA from the DNA–
protein complexes from all the samples including the input and
negative control was reverse cross-linked by incubation with 2 μL of
Proteinase K for 2 h at 65 °C. The crude DNA extract was eluted and
then washed several times with wash buffer containing ethanol (pro-
vided with the kit) followed by puriﬁcation with the use of DNA spin
columns provided by the manufacturer. The pure DNA was eluted out
of the DNA spin columns using 50 μL of the DNA elution buffer provided
in the kit. 1 μL of the puriﬁedDNAwas used for DNA concentration anal-
ysis using the “Quant-iT™ dsDNA” Assay kit from Invitrogen (Carlsbad,
CA). The DNA fragment size was determined by electrophoresis on a
1.2% agarose FlashGelR system (Lonza, Rockland, ME). The relative
abundance of the NF-κB p65 antibody precipitated chromatin contain-
ing the NF-κB binding site in the BACE1 promoter region was
determined by qPCR using an iQ SYBR Green Supermix kit following
the manufacturer's instructions (BioRad, Hercules, CA) and sequence
speciﬁc primers (Table 1). The ampliﬁcation was performed using an
iCycler iQMulticolor Real Time PCRDetection System (BioRad, Hercules,
CA). The fold enrichment of the boundNF-κB in the BACE1 promoter re-
gion was calculated using the ΔΔCt method (Livak and Schmittgen,
2001) which normalizes ChIP Ct values of each sample to the % input
and background.
2.7. SIRT1 activity assay
SIRT1 substrates exhibit no consensus amino acid sequence that can
distinguish them from SIRT2, SIRT6, or SIRT7 substrates. In this study,
we used a SIRT1 activity assay kit from Sigma Aldrich as per
manufacturer's protocol. The kit is furnished with a synthetic peptide
that is shown to be deacetylated by SIRT1 but not by other recombinant
sirtuins. Therefore, it is reasonable to deduce that we are measuring
SIRT1 activity exclusively in our nuclear lysates. We used our nuclear
lysates containing native situins for the assay. Whether there are
differences between the activities of the native or recombinant sirtuins
toward this synthetic peptide is beyond the scope and focus of our
study. SH-SY5Y treated cells were extracted by trypsinization and
nuclear homogenates were prepared using NE-PER protein extraction
reagent supplemented with protease and phosphatase inhibitors.
Protein concentrations cell homogenates were determined with BCA
protein assay. A total of 25 μL of this homogenate was added to each
well of the ELISA plate containing 50 μL of for the assay buffer and 5 μL
of NAD+. To each well 20 μL of SIRT1 substrate mix was added andthe platewas incubated at room temperature for 2 h followed by the ad-
dition of 10 μL of developing solution that unmasks the ﬂuorescent
group released by SIRT1 deacetylase activity. The plate was incubated
at room temperature for 20 min and ﬂuorescence of each well was
recorded with an excitation wavelength of 360 nm and emission wave-
length 450 nm. The assay was performed in quadruplet with half of the
wells serving as blanks towhich the developing solutionwas not added.
The net ﬂuorescence was obtained by subtracting the ﬂuorescence of
the blank from the respective samples. The net ﬂuorescence was
normalized to total protein content to yield the SIRT1 total activity.
Total activity is expressed as RFUpermg protein. To derive SIRT1 specif-
ic activity values, total activity values were normalized to the SIRT1
content as determined by Western blotting. Unit value was assigned
to control and the magnitude of differences among the samples is
expressed relative to the unit value of control cells.2.8. Luciferase reporter assays
Constructs encoding NF-κB response element and human BACE1
promoter conjugated to the ﬁreﬂy luciferase gene were used in the
study. Human neuroblastoma SH-SY5Y cells were plated in 96-well
plates at a density of 2 × 104 cells/well. The cells were transfected
when 80% conﬂuent with 0.25 μg of reporter constructs. Respective
non-inducible reporter constructs containing constitutively expressing
Renilla luciferase were used as negative internal controls. Constitutively
expressing GFP constructs were used as positive control to determine
transfection efﬁciency. Cells were incubated for 24 h with Opti-MEM
serum free medium (Invitrogen, Carlsbad, CA) containing the reporter
constructs dissolved in transfection reagent. After 24 h the medium
was changed and the cells were incubated in normal DMEM/F12
medium containing 10% FBS and cells were treated with the different
treatment regimens. The cells were treated in triplicate and harvested
24 h later and subjected to dual-luciferases assay. The dual-luciferase
assay was performed using a “Dual-Luciferase Reporter Assay System”
from Promega (Madison, WI). The luminescence recorded is expressed
as Relative Luminescence Units (RLU) and normalized to per mg
protein. Unit valuewas assigned to control and themagnitude of differ-
ences among the samples is expressed relative to the unit value of
control cells.2.9. Statistical analysis
The signiﬁcance of differences among the samples was assessed by
One Way Analysis of Variance (One Way ANOVA) followed by Tukey's
post-hoc test. Statistical analysis was performed with GraphPad Prism
software 4.01. Quantitative data for Western blotting analysis are pre-
sented as mean values ± S.E.M with unit value assigned to control
and the magnitude of differences among the samples being expressed
relative to the unit value of control. Quantitative data for RT-PCR analy-
sis are presented as mean values ± S.E.M, with reported values being
the product of absolute value of the ratio of SIRT1 mRNA or BACE1
mRNA to GAPDH mRNA multiplied by 1,000,000.
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3.1. Leptin increases SIRT1 expression levels and activity
This study ﬁrst tested the extent to which leptin regulates SIRT1
expression levels and activity in SH-SY5Y neuroblastoma cells. Lep-
tin treatment results in a 2.5-fold increase in SIRT1 protein levels in
the nuclear extracts as determined byWestern blotting and densito-
metric analysis (Fig. 1a, b). The nuclear extracts were subjected to
detect the presence of Bcl-2 protein to determine the extent of mito-
chondrial fraction contaminating the nuclear fractions. We did not
detect the presence of Bcl-2 in our nuclear fractions by immunoblot
analysis (data not shown). To determine if these changes were tran-
scriptional in nature, we performed Real Time RT-PCR. Real Time RT-
PCR analysis shows a 4-fold increase in SIRT1mRNA (Fig. 1c). To cor-
relate the increase in SIRT1 levels upon leptin treatment with en-
hancement of its activity, we subsequently performed a SIRT1
activity assay (Fig. 1d). Leptin treatment elicited a 4.2-fold increase
in total activity of SIRT1 and a 1.7-fold increase in speciﬁc activity of
the SIRT1 enzyme (Fig. 1d). This suggests that besides increasing the
total activity of SIRT1 by increasing its protein levels, leptin treat-
ment also increased basal and intrinsic SIRT1 activity when normal-
ized to equivalent protein levels. Therefore, leptin elicited an
increase in SIRT1 expression levels as well as an increase in speciﬁc
activity of SIRT1.
3.2. Leptin decreases BACE1 expression via the activation of SIRT1
We have previously shown that leptin decreases BACE1 expression
levels in hippocampal organotypic slices [27]. To gain a mechanistic in-
sight and elucidate the signaling pathways commandeered by leptin to
evoke attenuation in BACE1 expression; this study assessed theFig. 1. Leptin increases SIRT1 expression and activity in SH-SY5Y cells. (a, b) Representative W
levels SIRT1 in the nuclear homogenates. (c) Real-time RT-PCR analysis demonstrates that le
demonstrates that leptin signiﬁcantly increases the total activity as well as speciﬁc activity of SIR
cell culture experiments (n = 4). **p b 0.01, ***p b 0.001 versus control.involvement of SIRT1 activation and signaling. To this end, SH-SY5Y
cells were treated with leptin in the presence and absence of the
SIRT1 inhibitor, sirtinol. Sirtinol is a selective inhibitor of SIRT1 (IC50
~ 131 μM) with no inhibitory effects on Class I, II, and IV Histone
deacetylases (HDACs) at 1 mM concentration [40–43]. Sitinol does not
speciﬁcally inhibit SIRT1, but also inhibits SIRT2 and exhibits higher af-
ﬁnity and potency toward SIRT2 (IC50 38 μM for SIRT2). However, there
is no evidence suggesting that leptin activates SIRT2. Therefore, the po-
tential abrogation in the effects of leptin in the presence of sirtinol in the
present study can be attributed to SIRT1, although further studies are
warranted to extricate the contribution of SIRT2 inmediating the effects
of leptin. Leptin treatment decreased BACE1 protein levels by ~32% in
SH-SY5Y cells (Fig. 2A, B). However, leptin failed to elicit any signiﬁcant
decrease in BACE1 protein levels in the presence of the SIRT1 inhibitor
sirtinol (Fig. 2a, b), thereby implicating SIRT1 activation in leptin-
induced attenuation in BACE1 expression levels. As BACE1 expression
levels are tightly regulated at the translational level [44], this study de-
terminedwhether the effects of leptin on the attenuation of BACE1 pro-
tein levels were transcriptional in nature. Leptin treatment elicited a
more pronounced mitigation in BACE1 mRNA expression (~55%)
(Fig. 2c). However, in cells concomitantly treated with sirtinol, leptin
evoked modest ~26% attenuation in BACE1 mRNA expression
(Fig. 2C). This suggests that leptin-induced mitigation of BACE1 mRNA
expression is contingent on SIRT1 activation and implicates leptin and
SIRT1 in the transcriptional regulation of BACE1. Consistent with the
positive role of SIRT1 in the attenuation of BACE1 expression, this
study found a ~33% increase in BACE1 mRNA expression (Fig. 2C) in
SH SY5Y cells treated with sirtinol alone. This demonstrates that SIRT1
negatively regulates basal BACE1 expression levels as well as leptin-
induced attenuation in BACE1 expression. However, sirtinol treatment
alone did not result in any signiﬁcant increase in BACE1 protein levels
(Fig. 2A, B).estern blot and densitometric analysis demonstrate that leptin signiﬁcantly increases the
ptin also signiﬁcantly increases the mRNA expression of SIRT1. (d) SIRT1 activity assay
T1. Data is expressed asMean+ S.E.M and includes determinationsmade in four separate
Fig. 2. Leptin decreases BACE1 expression levels in a SIRT1-dependent manner. (A, B) Rep-
resentative Western blot and densitometric analysis demonstrate that leptin signiﬁcantly
decreases the expression levels of BACE1 while concomitant treatment with the SIRT1 in-
hibitor sirtinol signiﬁcantly attenuates the leptin-induced decrease in BACE1 protein levels.
(C) Real-time RT-PCR analysis demonstrates that leptin elicits a signiﬁcantly profound
decrease in the mRNA expression of BACE1, while concomitant treatment with the SIRT1
inhibitor sirtinol signiﬁcantly reduces the leptin-induced decrease in BACE1mRNA expres-
sion.Data is expressed asMean+ S.E.M and includes determinationsmade in four separate
cell culture experiments (n = 4). *p b 0.05, ***p b 0.001 versus control; †p b 0.05 versus
leptin.
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dependent manner without altering the binding of NF-κB to the BACE1
promoter region
Multiple lines of evidence have established a positive role of the
transcription factor NF-κB in BACE1 transcription [13–20]. The
transcriptionally active NF-κB is a heterodimeric composite of two con-
stituting subunits, with heterodimers composed of p65 and p50 sub-
units being the most common and well characterized. In the basal
state NF-κB heterodimeric complex is sequestered in the cytosol by vir-
tue of its interaction with IκB proteins [45,46]. Stimulus speciﬁc activa-
tion of IκB kinases (IKKs) leads to phosphorylation, ubiquitination and
proteasomal degradation of IκB proteins thereby releasing and allowing
the nuclear translocation of the free NF-κB dimer [45,47]. In the nucleus,
the p65 subunit undergoes reversible acetylation at Lys122, Lys123,
Lys218, Lys221, Lys310, Lys314 and Lys315 residues that modulate thetranscriptional activity of NF-κB [48]. In the nucleus, acetylated p65 in-
teracts with co-activators p300/CBP and PCAF that positively regulate
NF-κB transcriptional activity [49–53]. Deacetylation of the p65 subunit
at Lys310 increases the interaction of p65 with the IκBα resident in the
nucleus and promotes the export of the p65-IκBα from the nucleus
into the cytosol leading to termination of NF-κB-mediated transcription
of target genes [48,54–56]. SIRT1 has been demonstrated to inhibit
NF-κB mediated transcription by deactetylating the Lys310 residue in
the p65 subunit [57]. We hypothesized that leptin may regulate BACE1
expression by inhibiting NF-κB mediated transcription via the activation
of SIRT1. To this end,weﬁrst determined the acetylation status of the p65
subunit of NF-κB in the nuclear homogenates of cells treated with leptin
in the presence and absence of the SIRT1 inhibitor sirtinol.We found that
leptin treatment reduces the levels of the acetylated-Lys310 p65 subunit
of NF-κB in the nucleus by ~26%, thereby suggesting leptin regulates
the nuclear retention of NF-κB (Fig. 3A, B). Sirtinol treatment resulted
in a 37% increase in nuclear levels of acetylated-Lys310 p65, suggesting
that SIRT1 negatively regulates the basal levels of acetylated-Lys310 p65
in the nucleus (Fig. 3A, B). Moreover, SH-SY5Y cells co-treated with
sirtinol and leptin did not exhibit reduction in acetylated-Lys310 p65
levels in the nucleus, but rather exhibited an increase in nuclear
acetylated-Lys310 p65 levels (~39%) to the same degree as cells treated
with sirtinol alone, thus implicating SIRT1 exclusively in the leptin-
induced reduction of acetylation of the Lys310 residue of p65 (Fig. 3A, B).
To further establish and characterize the effects of leptin on NF-κB
activation and BACE1 expression aswell as to elucidate the involvement
of SIRT1 inmediating these effects, a ChIP assaywasperformed to deter-
mine the extent of NF-κB binding to the κB sites in the BACE1 promoter
region. Leptin treatment did not induce any changes in binding of NF-κB
to the BACE1 promoter region (Fig. 3C). The SIRT1 inhibitor sirtinol also
did not elicit any changes in NF-κB binding to the BACE1 promoter
region (Fig. 3C). However, the lack of changes in binding of NF-κB to
the BACE1 promoter in response to leptin or sirtinolmay not necessarily
reﬂect the lack of NF-κB-mediated modulation of BACE1 expression. To
unequivocally implicate or extricate NF-κB as the mediator of leptin-
induced attenuation in BACE1 expression, a dual luciferase assay was
performed to assess NF-κB transcriptional activity and BACE1 promoter
activity. Dual-luciferase assay performed using a NF-κB reporter con-
struct revealed that leptin treatment signiﬁcantly attenuated NF-κB
transcriptional activity by ~25% (Fig. 3D). Furthermore, in sirtinol co-
treated cells, leptin failed to elicit reduction in NF-κB reporter activity,
thereby implicating SIRT1 in the leptin-induced mitigation of NF-κB re-
porter activity (Fig. 3D). This effect also positively correlates with the
acetylation status of the p65 subunit of NF-κB. Additionally, sirtinol
treatment alone resulted in a ~32% increase in NF-κB reporter activity,
further implicating SIRT1 in the negative regulation of basal NF-κB
transcriptional activity (Fig. 3D).
Dual luciferase using a BACE1 promoter construct also demonstrated
that leptin signiﬁcantly mitigated BACE1 promoter activity by ~47%
(Fig. 3E). Furthermore, this attenuation in BACE1 promoter activity by
leptin was contingent on SIRT1 activation as leptin evoked a modest
~20% decrease in BACE1 promoter activity in sirtinol co-treated cells
(Fig. 3E). Sirtinol treatment alone resulted in a ~29% increase in
BACE1 promoter activity, further implicating SIRT1 in the basal expres-
sion of BACE1 (Fig. 3E). The aforementioned results also suggest that
levels of acetylated-Lys310 p65 correlate better with NF-κB transcrip-
tional activity and BACE1 promoter activation than the extent of NF-
κB binding to the BACE1 promoter.
3.4. Leptin decreases Aβ levels by SIRT1 activation
Wehave previously demonstrated that treatmentwith leptin results
in a reduction of both Aβ42 and Aβ40 levels in hippocampal
organotypic slices [27]. This study investigated the involvement of
SIRT1 in leptin-induced attenuation in Aβ levels. Therefore, this study
measured the attenuation in Aβ42 and Aβ40 levels in the presence
Fig. 3. Leptin reduces NF-κB acetylation and subsequently decreases NF-κB-mediated BACE1 expression in a SIRT1-dependent manner. (A, B) Representative Western blot and densito-
metric analysis demonstrate that leptin signiﬁcantly decreases the levels of acetylated-Lys310 p65 subunit in the nuclear homogenates while concomitant treatment with the SIRT1 inhib-
itor sirtinol completely abrogates the leptin-induced reduction in nuclear acetylated-Lys310 p65. (C) ChIP analysis demonstrates that neither leptin nor sirtinol signiﬁcantly changes the
binding of NF-κB in the BACE1 promoter region. (D) Dual luciferase assay demonstrates that leptin signiﬁcantly decreases the NF-κB transcriptional activity as measured by a signiﬁcant
decrease in NF-κB reporter activity, while concomitant treatment the SIRT1 inhibitor sirtinol completely abrogates the leptin-induced mitigation in NF-κB reporter activity. (E) Dual lu-
ciferase assay demonstrates that leptin signiﬁcantly decreases the BACE1 promoter activity, while concomitant treatment with the SIRT1 inhibitor sirtinol signiﬁcantly attenuates
the leptin-induced decrease in BACE1 promoter activity. Data is expressed as Mean + S.E.M and includes determinations made in four separate cell culture experiments
(n = 4). *p b 0.05, **p b 0.01versus control; †p b 0.05, ††p b 0.01, †††p b 0.001 versus leptin.
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evoked a ~62% decrease in intracellular Aβ42 and a ~48% decrease in
levels intracellular Aβ40 levels as determined by ELISA immunoassay
(Fig. 4A, B). Leptin also elicited a ~71% decrease in Aβ42 and a 54% de-
crease in Aβ40 secreted in the media (Fig. 4C, D). However in the pres-
ence of the SIRT1 inhibitor sirtinol, leptin elicited only a ~38% decrease
in intracellular Aβ42 and a 36% decrease in intracellular Aβ40 levels
compared to basal levels as determined by ELISA immunoassay
(Fig. 4A, B). Furthermore, the SIRT1 inhibitor sirtinol also signiﬁcantly
attenuated the leptin-induced decrease in secreted Aβ42 and Aβ40. In
the presence of the SIRT1 inhibitor sirtinol, leptin elicited a ~42% de-
crease in secreted Aβ42 and a 35% decrease in secreted Aβ40 levels
compared to basal levels These ﬁndings suggest that SIRT1 plays a
major role in the leptin-induced decrease in Aβ levels.
3.5. Discussion
This study elucidated and delineated the molecular pathways and
signal transduction mechanisms involved in the leptin-inducedattenuation in BACE1 expression and subsequent mitigation in Aβ gen-
esis. This study demonstrates that leptin treatment increases the ex-
pression levels and activity of the master metabolic regulator SIRT1,
which subsequently results in the decreased NF-κB mediated expres-
sion of BACE1. This study further demonstrates that leptin-induced re-
duction in Aβ levels is contingent on SIRT1 activation as the SIRT1
inhibitor signiﬁcantly abrogated the effect of leptin on Aβ. This study
demonstrates for theﬁrst time the presence of a leptin-SIRT1-NF-κB sig-
naling cascade that is involved in the regulation of BACE1 expression
and Aβ production.
This study demonstrates that leptin increases SIRT1 expression as
well as SIRT1 speciﬁc activity. There is evidence that leptin activates
SIRT1 in hypothalamic POMC neurons [33] and leptin receptor mutant
db/dbmice exhibit deﬁcits in SIRT1 activation [35]. Leptin also activates
SIRT1 in primary cell lines derived from themurine hypothalamus [58],
suggesting that leptin activates SIRT1 in non-cancer cells or in cells de-
void of oncogenic potential as cancer cells are known to express sirtuins.
Furthermore, leptin activates 5′-AMP-activated protein kinase (AMPK)
[59–63], a known activator and inducer of SIRT1 activity [64–67].
Fig. 4. Leptin induced reduction in Aβ levels is partially contingent on SIRT1 activation. (A, B) ELISA immunoassay clearly demonstrates that leptin signiﬁcantly decreases the levels of
intracellular Aβ42 and Aβ40, while concomitant treatment with the SIRT1 inhibitor sirtinol mitigates the leptin-induced decrease in intracellular Aβ42 and Aβ40. (C, D) ELISA immuno-
assay clearly shows that leptin signiﬁcantly decreases the levels of secreted forms of Aβ42 and Aβ40, while co-treatment with the SIRT1 inhibitor sirtinol signiﬁcantly attenuates
the leptin-induced decrease in secreted Aβ42 and Aβ40. Data is expressed as Mean + S.E.M and includes determinations made in four separate cell culture experiments
(n = 4). *p b 0.05, **p b 0.01, ***p b 0.001 versus control; †p b 0.05, ††p b 0.01 versus leptin.
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augmenting the activity of SIRT1, leptin also increases the expression
of SIRT1. SIRT1 has been shown to attenuate Aβ production by increas-
ing the expression levels of the α-secretase, ADAM10 [21], thereby
shunting and facilitating non-amyloidogenic processing of AβPP.
Overexpression of SIRT1 confers neuroprotection from toxic insults
and precludes learning deﬁcits in animal models of AD [22]. SIRT1 has
been demonstrated to inhibit NF-κB signaling andNF-κBmediated tran-
scription of target genes via the deacetylation of thep65 subunit [12,57].
A multitude of studies have implicated the activation of NF-κB signaling
in the positive regulation of BACE1 transcription [13–20], thereby sug-
gesting that SIRT1 may regulate Aβ production by modulating BACE1
expression via NF-κB signaling. As leptin treatment increased the
expression and activation of SIRT1, and given that SIRT1 negatively
regulates NF-κB mediated transcription of target genes, this study
hypothesized that leptin may attenuate BACE1 expression and subse-
quent Aβ production by increasing SIRT1-induced repression of NF-κB
mediated transcription of BACE1. To this end, the study next investigat-
ed the levels of the acetylated-Lys310 p65 subunit of NF-κB in the nucle-
ar homogenates in response to leptin treatment in the presence and the
absence of the SIRT1 inhibitor sirtinol. It is posited that acetylation of
Lys310 residue in the p65 subunit increases the DNA-binding afﬁnity,
efﬁciency, and augments NF-κB mediated transcription of target
genes [49–53]. SIRT1-induced deacetylation of the p65 subunit at
Lys310 decreases the binding afﬁnity to the DNA as well as to other
transcriptional co-activators such as p300/CBP and PCAF, while in-
creasing the interaction of p65 with the IκBα resident in the nucleus
thereby promoting the export of the p65-IκBα complex from the nu-
cleus into the cytosol leading to termination of NF-κB-mediated
transcription of target genes [48,54–56]. Leptin decreased the levels
of acetylated-Lys310 p65 in the nuclear extracts and this reductionwas contingent on SIRT1 activity. The inhibition of SIRT1 resulted
in a ~37% increase in the nuclear levels of acetylated-Lys310 p65 sug-
gesting that SIRT1 regulates the basal acetylation of the p65 subunit
in the nucleus. Interestingly, leptin treatment in SH-SY5Y cells co-
treated with the SIRT1 inhibitor also exhibited a ~39% increase in
acetylated-Lys310 p65 nuclear levels, thereby suggesting the requi-
site nature of SIRT1 in the leptin-induced deacetylation of p65.
To further determine the relationship between the increased or de-
creased acetylation of the p65 subunit of NF-κB at Lys310 and degree of
binding to the κB sites in the BACE1 promoter region, a ChIP assay
was performed to assess the extent of p65-bound to the BACE1 promot-
er region in response to leptin treatment in the presence and absence of
the SIRT1 inhibitor. Interestingly, neither leptin nor SIRT1 effectuated
any changes in the binding of the p65 subunit to the κB binding sites
in the BACE1 promoter region. As lack of changes in binding of NF-κB
to the promoter regions of target genes such as BACE1 may or may
not reﬂect the lack of NF-κB-mediated regulation, a dual luciferase
assay was performed to assess NF-κB transcriptional activity and
BACE1 promoter activity, to unequivocally implicate or extricate NF-
κB as the mediator of leptin-induced attenuation in BACE1 expression.
Leptin treatment signiﬁcantly reduced NF-κB reporter activity by
~25%. On the contrary, inhibition of SIRT1 resulted in ~32% increase in
NF-κB reporter activity and moreover, leptin treatment in SIRT1-
inhibited cells also produced similar a ~20% increase. This suggests
that SIRT1 not only mediates the basal NF-κB transcriptional activity,
but also exclusively mediates the leptin-induced mitigation in NF-κB
activity. This study also determined the BACE1 promoter activity in
response to leptin treatment in the presence and absence of the SIRT1
inhibitor using the dual-luciferase assay system. Leptin treatment
evoked a signiﬁcantly profound ~47% decrease in BACE1 promoter
activity. However, leptin treatment only elicited a ~20% reduction in
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leptin-induced attenuation in BACE1 promoter activity is contingent
on SIRT1 activity. Furthermore, the SIRT1 inhibitor induced a ~29% in-
crease in BACE1 promoter activity, further implicating SIRT1 in the
basal regulation of BACE1 promoter activity.
The cleavage of Amyloid-β Precursor Protein (APP) by BACE1 is the
rate limiting step in Aβ production. Therefore, BACE1 expression levels
are tightly correlated with Aβ levels. We have demonstrated that leptin
signiﬁcantly reduces Aβ levels in hippocampal organotypic slices from
adult rabbits [27]. This study determined the involvement of SIRT1 in
leptin-induced attenuation in Aβ levels. Consistent with our previous
study [27], leptin induced a profound signiﬁcant attenuation in both,
the secreted and intracellular levels of Aβ42 andAβ40. Leptin treatment
failed to evoke a similar magnitude of reduction in Aβ levels in SIRT1-
inhibited cells. However, leptin did signiﬁcantly mitigate Aβ levels in
SIRT1 inhibited cells, suggesting that SIRT1 is only partly responsible
for the leptin-induced abrogation in Aβ levels. This suggests that other
signaling cascades or pathways are actuated by leptin that reduce Aβ
levels independent of the involvement of SIRT1.
The denouement of this study that, leptin increases SIRT1 expression
levels and activity, bears profound implications in AD. SIRT1 is widely
implicated in aging, glucose and lipid metabolism, apoptosis and cell
survival, cell senescence, DNA repair, as well as neurogenesis [68,69] –
biological processes that are intricately involved in the pathogenesis of
AD. Furthermore, leptin has been demonstrated to regulate the same
aforementioned biological processes involved in AD. It is therefore not
outside the realm of possibility that leptin may indeed impinge on
these biological / physiological processes via the activation of SIRT1. Re-
cently Greco and colleagues demonstrated that leptin regulates tau
phosphorylation via the AMPK/SIRT1 signaling cascade [63]. This
study demonstrates for the ﬁrst time the presence of a leptin/SIRT1/
NF-κB pathway that regulates BACE1 expression and subsequent Aβ
genesis. This study also demonstrates that in addition to increasing
the activity of SIRT1, leptin also increases SIRT1 expression levels. Fur-
ther studies are warranted to delve into and elucidate the signaling
mechanisms that are involved in the regulation of leptin-induced up-
regulation in SIRT1 expression, SIRT1 deacetylates and consequently
regulates the subcellular localization and activities of a plethora of tran-
scription factors that include NF-κB, p53, PPARγ, and PGC1α among
others. PPARγ [70,71] and PGC1α [72] have been demonstrated to
attenuate BACE1 expression. Interestingly, leptin has been shown to
modulate PPARγ expression [23] and PGC1α [73–75]. Therefore, further
studies are warranted to determine the involvement of PPARγ and
PGC1α in the SIRT1-dependentmodulation of BACE1 expression by lep-
tin. Furthermore, in this study leptin-induced reduction in Aβ exhibited
a SIRT1-independent component or signaling cascade. This could be at-
tributed to the effects of leptin on other cellular processes such as BACE1
activity, alteration in composition of lipid membranes, autophagy, as
well as oxidative stress that may regulate Aβ levels independent of
SIRT1 activity.
In summary, this study demonstrates that leptin increases the ex-
pression and activity of SIRT1 resulting in decreased NF-κB mediated
transcription of BACE1. Leptin decreased BACE1 protein levels and
mRNA expression by attenuating NF-κB transcriptional activity and
BACE1 promoter activity in a SIRT-dependent manner. Leptin also re-
duced Aβ levels in a SIRT1 dependent fashion, however the stringency
for SIRT1 activity in leptin-induced reduction in Aβ was less rigorous.
This study provides a valuable insight into the signal transduction path-
ways thatmodulate BACE1 expression andAβ genesis, which is of utter-
most relevance to the etiopathogenesis of AD.Disclosure statement
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